产品
编 号：F762498
分子式：C19H15F4NO3
分子量：381.32
分子式：C19H15F4NO3
分子量：381.32
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
1980
In-stock
1mg
818
In-stock
5mg
1800
In-stock
10mg
3000
In-stock
25mg
5850
In-stock
50mg
9000
In-stock
100mg
13500
In-stock
结构图
CAS No: 2708177-73-3
产品详情
生物活性：
PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).
体内研究：
PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO).PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO.Animal Model:Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:5 and 10 mg/kg
Administration:Oral gavage; daily, for 6 weeks
Result:Promoted the recovery of CBF after BCCAO.
Animal Model:Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:5 and 10 mg/kg
Administration:Oral gavage; daily, for 5 days
Result:Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group.Improved cognitive deficits in CCH rat model.
体外研究：
PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells.PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway.
PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).
体内研究：
PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO).PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO.Animal Model:Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:5 and 10 mg/kg
Administration:Oral gavage; daily, for 6 weeks
Result:Promoted the recovery of CBF after BCCAO.
Animal Model:Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model
Dosage:5 and 10 mg/kg
Administration:Oral gavage; daily, for 5 days
Result:Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group.Improved cognitive deficits in CCH rat model.
体外研究：
PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells.PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备